Melanotan II
Melanotan II scored 4.6 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Peptide → Neuropeptide.
Melanotan II is a fast tanning and sexual-response peptide with a harsher safety tradeoff; Nelson 2012 reported rhabdomyolysis after a 6 mg injection. Its appetite and libido effects may be noticeable, but this report treats unregulated use as high risk.
What is Melanotan II?
Melanotan II is an unapproved non-selective melanocortin peptide that can darken skin, suppress appetite, and produce sexual-response effects, but the same receptor breadth creates a serious safety problem. Melanotan II activates several melanocortin receptors, including MC1R for pigmentation and central pathways tied to appetite and libido. Melanotan II earns a caution score because early human efficacy signals are small and verified case reports include PRES, rhabdomyolysis, renal infarction, melanoma, and dysplastic-nevus proliferation. Melanotan II also needs context because readers may approach the report from different goals: symptom relief, performance, risk reduction, or curiosity about a mechanism. The score does not tell a reader to use Melanotan II; the score shows where the evidence, practical burden, and safety concerns currently meet. That matters because the same intervention can look attractive in one subgroup and poorly matched in another.
The practical distinction matters because Melanotan II intrinsic pharmacology must be scored separately from access and sourcing. The BioHarmony score reflects the compound evidence and on-target receptor effects, while the Verdict section separately flags product-quality and sourcing cautions.
Additional evidence links in this report include MC4R feeding mechanism. Melanoma case report. Rhabdomyolysis case report.
PRES case report. Renal infarction case report. Ischemic priapism case report..
Those comparisons help place Melanotan II beside interventions with different tradeoffs in sleep, skin, immune, recovery, and peptide-adjacent use cases.
Organic erectile-dysfunction sessions produced 12 erections across 19 MT-II exposures versus 1 across 21 placebo exposures.
A renal infarction case described roughly 50% right-kidney infarction after cumulative MT-II exposure over 6 months.
"Melanotan and the posterior reversible encephalopathy syndrome."
"Melanotan II injection resulting in systemic toxicity and rhabdomyolysis."
"Use of melanotan I and II in the general population."
Terminology
- MT-II / MT2: Common shorthand for Melanotan II, the same synthetic peptide sold as tanning injections or nasal sprays.
- Bremelanotide: An FDA-approved melanocortin agonist (for low sexual desire in some women) that is related to, but not the same as, the unapproved Melanotan II.
- MC1R: Melanocortin 1 receptor, the skin-pigment receptor that drives the tanning effect.
- MC4R: Melanocortin 4 receptor, a brain receptor tied to appetite and sexual-response signaling.
- Non-selective agonist: A compound that activates several related receptors at once (here MC1R, MC3R, MC4R, MC5R), which is why effects and risks spread well beyond tanning.
- PRES: Posterior reversible encephalopathy syndrome, a rare neurologic emergency reported in a melanotan case.
- Rhabdomyolysis: Rapid muscle breakdown that floods the blood with proteins and can injure the kidneys.
- Priapism: A prolonged, painful erection that is a urologic emergency and can permanently damage tissue.
- Dysplastic nevus: An atypical mole that carries higher melanoma risk and can change under melanocortin stimulation.
How do you take Melanotan II?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| subcutaneous injection | unapproved peptide solution | not established | microgram-to-milligram cycles |
| intranasal | unapproved spray | not established | variable |
Protocols
Short Cycle Initiation Anecdotal
- Dose
- Variable
- Frequency
- Variable
- Duration
- Usually days to weeks
The report does not recommend a protocol; this describes community practice only.
Clinical Sexual-Function Studies Clinical
- Dose
- Single supervised injections
- Frequency
- Acute study sessions
- Duration
- Short term
Small early studies used monitored settings, not home peptide use.
How this score is calculated →
What are the benefits of Melanotan II?
Upside contribution: 2.25
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.8 | 0.950 | |
| Breadth | 15% | 3.2 | 0.480 | |
| Evidence | 25% | 3.0 | 0.750 | |
| Speed | 10% | 4.2 | 0.420 | |
| Durability | 10% | 2.0 | 0.200 | |
| Bioindividuality | 15% | 3.0 | 0.450 | |
| Total | 3.250 |
Upside Rationale
Melanotan II upside is fast and noticeable, and the human signal, while limited, is real. Dorr et al. 1996 tested only three male volunteers in a pilot MT-II study and still saw clear tanning, yawning, nausea, and spontaneous erections. The libido and tanning signals are strong enough to score with some confidence, even though they come from small early trials and case-adjacent experience rather than a modern, regulated program. That is why Melanotan II has high speed with moderate overall confidence.
Efficacy (3.8/5.0): Melanotan II efficacy is real and fairly robust for tanning and sexual-response endpoints, even though the best direct studies are small. Wessells et al. 2000 reported 12 erections with MT-II versus 1 with placebo across monitored episodes, and tanning response is consistent across the early human work. Melanotan II clearly does what users take it for; the limitation is trial size and the lack of an approval-grade program, not whether the effect appears.
Breadth of Benefits (3.2/5.0): Melanotan II breadth is moderate because pigmentation, libido, appetite, and possibly body-composition signals all flow from melanocortin receptor activity. That same receptor spread is double-edged: it links to nausea, yawning, blood-pressure symptoms, priapism, and neurologic concern on the downside. The multi-system reach gives it genuine breadth, but the poor receptor selectivity means benefit and side effect ride together.
Evidence Quality (3.0/5.0): Melanotan II evidence quality is moderate. Early human trials were small but consistent on the core endpoints, and bremelanotide comparator data help interpret melanocortin sexual-response biology with an approved, regulated reference point. Modern regulated MT-II trials are absent and much current use happens outside medical systems, which caps the score, but the mechanism and direction of effect are reasonably well established.
Speed of Onset (4.2/5.0): Melanotan II speed is high because nausea, flushing, appetite changes, libido, erections, and tanning initiation can appear quickly. Dorr et al. 1996 saw acute yawning, nausea, and spontaneous erections in the pilot setting. Fast feedback is part of the appeal, but fast side effects also make unsupervised escalation risky.
Durability (2.0/5.0): Melanotan II durability is limited because tanning requires repeated exposure and fades over time, appetite effects do not reliably persist, and libido effects are acute. Users often cycle because chronic use increases practical concern around moles, pigmentation, and side effects. A benefit that requires repeated gray-market injections cannot score high for durability.
Bioindividuality Upside (3.0/5.0): Melanotan II bioindividuality is moderate because fair skin, baseline nevi, libido goals, nausea sensitivity, blood-pressure sensitivity, and appetite response all shape the experience. Melanotan II has obvious strong responders, but it lacks validated screening rules. That uncertainty matters because a strong responder can also be a strong side-effect responder.
What are the risks & downsides of Melanotan II?
Downside contribution: 2.65 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 3.7 | 1.110 | |
| Side effects | 15% | 3.8 | 0.570 | |
| Cost | 5% | 2.5 | 0.125 | |
| Effort | 5% | 3.0 | 0.150 | |
| Opportunity | 5% | 2.8 | 0.140 | |
| Dependency | 15% | 2.0 | 0.300 | |
| Reversibility | 25% | 2.3 | 0.575 | |
| Total | 2.970 | |||
| Harm subtotal × 1.4 | 3.577 | |||
| Opportunity subtotal × 1.0 | 0.415 | |||
| Combined downside | 3.992 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 2.652 |
Downside Rationale
Melanotan II downside is severe because several verified case reports involve medically urgent or potentially permanent outcomes after MT-II exposure, and the melanocortin mechanism carries a specific, demonstrated melanoma and dysplastic-nevus signal that has to be taken at face value. Nelson et al. 2012 documented systemic toxicity and rhabdomyolysis after a 6 mg injection, while Kaski and Peters reported PRES and renal infarction. Priapism is handled as an on-target side-effect extension rather than a Safety Risk driver. The nevus and pigmentation concern is the one to keep honest: melanocortin activation changing moles is mechanism-plausible and case-documented, not generic class theory.
Safety Risk (3.7/5.0): Melanotan II Safety Risk is high because verified case reports include melanoma or dysplastic-nevus proliferation, rhabdomyolysis, PRES, and renal infarction. Kaski et al. 2013 and Peters et al. 2020 are central to the score. The melanocortin-driven nevus and melanoma signal is the specific, demonstrated concern that keeps this elevated rather than generic. Multiple distinct severe signals exist, but case-report causation uncertainty keeps Melanotan II from scoring at the absolute ceiling.
Side Effect Profile (3.8/5.0): Melanotan II side effects are common and often immediate, especially nausea, flushing, yawning, appetite suppression, spontaneous erections, libido shifts, skin darkening, and mole changes. The pro-erectile effect is on-target melanocortin-MC4 pharmacology, similar to the bremelanotide pathway, but prolonged painful erection can become ischemic priapism and require emergency care. Mallory et al. 2021 documents that over-extension risk, so priapism belongs here and in Verdict.
Financial Cost (2.5/5.0): Melanotan II financial cost is moderate because there is no legitimate approved channel for the common tanning or libido use cases, and the practical path usually includes supplies, skin monitoring, and extra caution.
Time/Effort Burden (3.0/5.0): Melanotan II effort is high because use usually involves reconstitution, injection or nasal dosing, dose escalation, UV timing, skin monitoring, and emergency awareness. Melanotan II also requires the user to distinguish expected side effects from urgent symptoms such as severe headache, dark urine, muscle pain, visual changes, or prolonged erection.
Opportunity Cost (2.8/5.0): Melanotan II opportunity cost is high because safer alternatives exist for the main goals: Melanotan I for pigment-focused use, conventional libido workups for sexual function, and diet or GLP-1 pathways for appetite and body composition. Melanotan II can crowd out safer, better-studied choices because the fast effects feel convincing.
Dependency/Withdrawal (2.0/5.0): Melanotan II dependency risk is moderate-to-low because there is no classic addiction pattern, but users can become functionally attached to the tan, appetite suppression, or libido effect. Cycles can invite repeated use before vacations or events. That pattern is not withdrawal, but it can still create repeated exposure to a high-risk peptide.
Reversibility (2.3/5.0): Melanotan II reversibility is concerning because nausea resolves, but renal infarction, rhabdomyolysis complications, melanoma diagnosis, PRES-related injury, or persistent pigment changes may not reverse cleanly. Prolonged erection risk is handled in Side Effect Profile because it is an over-extension of intended MC4 pharmacology. Reversibility scores moderate because most acute effects clear, while a minority of intrinsic case-report outcomes can leave lasting harm.
Is Melanotan II worth it?
Melanotan II is a caution-tier compound: effective enough to tempt use, risky enough to demand restraint. It reliably tans skin, blunts appetite, and drives libido, but it does all of that by activating melanocortin receptors throughout the body, and the documented harms (PRES, rhabdomyolysis, renal infarction, melanoma, priapism) are too serious to wave off as ordinary tolerability issues. The score reflects the compound itself; sourcing and product-quality cautions sit in the notes below and are not folded into the dimension scores.
✅ Best for: Experienced users who already understand peptide sourcing, have a dermatologist watching their skin and moles, can recognize emergency symptoms, and treat MT-II as a short initiation tool rather than a chronic lifestyle product. It is most relevant when libido or appetite suppression is the actual goal, since those effects come from receptors that Melanotan I largely skips.
❌ Avoid if: You have a history of melanoma, atypical or changing moles, uncontrolled blood pressure, kidney disease, seizures or severe migraines, prior priapism, sickle-cell disease, or anticoagulant use without oversight, or if you are pregnant, breastfeeding, or far from urgent care. Also avoid nasal sprays and unlabeled vials when sterility, identity, dose accuracy, or contamination controls are unclear; those are supply-chain cautions, not part of the score.
What is Melanotan II best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Skin / Beauty: 6.4/10
Score: 6.4/10Melanotan II has a clear tanning effect, but the skin-beauty score is capped by safety and regulatory uncertainty. Human melanotropin trials showed tanning from subcutaneous administration, and the early MT-II pilot reported pigmentation along with nausea and spontaneous erections (Dorr et al. 1996). The same mechanism that darkens skin can also darken nevi, so aesthetic benefit and dermatologic monitoring are inseparable. Melanotan II should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence.
Libido / Sexual Health: 6.1/10
Score: 6.1/10Melanotan II has one of the more direct human libido and erection signals among gray-market peptides. In men with organic erectile dysfunction, MT-II produced 12 erections across 19 treated episodes versus 1 across 21 placebo episodes (Wessells et al. 2000). The score stays below strong because the compound is unapproved, nausea is common, and ischemic priapism case reports change the risk discussion. Melanotan II should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence.
Body Composition / Fat Loss: 5.0/10
Score: 5.0/10Melanotan II gets a borderline body-composition score because melanocortin signaling can suppress appetite, and animal MC4R work connects the pathway to feeding. The classic Nature paper showed melanocortinergic neurons influence feeding and obesity biology (Fan et al. 1997). Human fat-loss trials for MT-II are not the evidence base, so this score reflects appetite signal plausibility rather than a proven body-composition protocol. Melanotan II should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence.
Antioxidant / Oxidative Stress: 5.0/10
Score: 5.0/10Melanotan II has a limited antioxidant-adjacent score through UV-pigmentation biology rather than systemic redox evidence. The tanning mechanism increases melanin, which can reduce UV injury in the skin, but MT-II lacks the regulated EPP evidence that supports afamelanotide. The case-report literature also forces a narrower interpretation because melanoma and dysplastic-nevus reports appear in users of melanotan products (Hjuler and Lorentzen 2014). Melanotan II should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence.
Frequently Asked Questions
Does Melanotan II actually make you tan?
Yes. Melanotan II activates the MC1R skin receptor, which pushes melanocytes to make more eumelanin, so most users darken with far less UV exposure than usual. In Dorr et al. 1996, short low-dose courses produced measurable pigmentation in people. The catch is that the same receptor activity also stimulates existing moles, which is part of why melanoma and atypical-mole cases show up in the literature.
Does Melanotan II affect erections and libido?
It does, and that is one of its best-documented effects. In Wessells et al. 1998, men with psychogenic erectile dysfunction held tip rigidity far longer on the peptide than on placebo, and Wessells et al. 2000 saw erections after 12 of 19 injections versus 1 of 21 placebo doses. The pro-erectile drive comes from central MC4R activity, not from blood-flow drugs like sildenafil.
Why does Melanotan II suppress appetite?
Appetite suppression comes from the same central melanocortin signaling that controls feeding. Fan et al. 1997 showed that melanocortin neurons tonically hold feeding down, and Melanotan II hits those MC4R pathways. Many users notice reduced hunger and some nausea early in a cycle. It was never a weight-loss drug, though, and the appetite effect is a side consequence of broad receptor activation, not a clean fat-loss tool.
Is Melanotan II safe?
This is its biggest problem. Verified case reports tie Melanotan II to serious harms: rhabdomyolysis in Nelson et al. 2012, PRES in Kaski et al. 2013, renal infarction in Peters et al. 2020, and melanoma in Hjuler et al. 2014. These are rare but severe, and there is no long-term human safety data. I treat it as a high-caution compound, not a casual one.
Can Melanotan II cause skin cancer or change my moles?
There is real concern here. Because Melanotan II stimulates melanocytes everywhere, it can darken and change existing moles, and Hjuler et al. 2014 reported a melanoma case linked to its use. That does not prove it causes melanoma in everyone, but anyone with a personal or family history of melanoma, lots of atypical moles, or changing lesions should stay away and get a skin check rather than experiment.
Is Melanotan II the same as the nasal tanning sprays people buy online?
Often yes, and that is a quality trap. Nasal sprays and unlabeled vials sold as tanning products are usually gray-market Melanotan II with no guarantee of identity, dose accuracy, sterility, or contamination control. The compound risk is one thing; the sourcing risk is another. An underdosed or contaminated vial adds infection and impurity hazards on top of the receptor effects, which is why product quality is flagged separately from the score.
How is Melanotan II different from Melanotan I?
Melanotan I (afamelanotide) is more selective toward pigmentation, while Melanotan II is non-selective and also hits the receptors behind appetite and sexual response. That broader reach is what makes MT-II feel more potent and faster, but it also widens the side-effect and safety profile. Some users run a short MT-II initiation and then switch to Melanotan I for the rest of a cycle to limit the extra receptor activity.
Can Melanotan II cause priapism?
Yes, and it is a genuine emergency. Because the peptide drives erections through central pathways, it can overshoot into priapism, a prolonged painful erection that can permanently damage penile tissue. Mallory et al. 2021 described an ischemic priapism case after a tanning injection that needed surgical decompression. An erection lasting more than four hours needs urgent medical care, not waiting it out.
What could change Melanotan II's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
Melanotan II would move upward only if dose-ranging, dermatology surveillance, and adverse-event follow-up clarified which risks are intrinsic, dose-dependent, and avoidable with monitoring. Melanotan II would move downward if additional renal, neurologic, ischemic, or melanoma reports accumulate, or if post-market bremelanotide data show class signals that map back to MT-II. The first dimensions to move would be Safety Risk, Reversibility, Evidence Quality, and Opportunity Cost.Melanotan II also needs context because readers may approach the report from different goals: symptom relief, performance, risk reduction, or curiosity about a mechanism For durability, the key question is whether benefits persist after the early window.The score does not tell a reader to use Melanotan II; the score shows where the evidence, practical burden, and safety concerns currently meet For durability, the key question is whether benefits persist after the early window.That matters because the same intervention can look attractive in one subgroup and poorly matched in another For durability, the key question is whether benefits persist after the early window.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| Better human dose-ranging separates benefit from severe case signals. | Evidence +0.5, Safety -0.2. | 4.8 / 10 ⚖️ Neutral |
| Long-term surveillance finds a clearer intrinsic safety problem. | Safety +0.7, Reversibility +0.4, Evidence unchanged. | 4.2 / 10 ⚠️ Caution |
| Dermatology monitoring reduces mole-related uncertainty. | Safety -0.2, Opportunity -0.2. | 4.7 / 10 ⚖️ Neutral |
| A large neutral RCT weakens the main claim. | Efficacy -0.5, Evidence -0.3, Breadth -0.3. | 4.4 / 10 ⚠️ Caution |
| Better responder rules emerge. | Bioindividuality +0.5, Opportunity -0.2. | 4.7 / 10 ⚖️ Neutral |
| Stronger dose and side-effect standards become routine. | Side Effects -0.4, Effort -0.3, Reversibility -0.2. | 4.8 / 10 ⚖️ Neutral |
Melanotan II lands at 3.7 / 10 ⚠️ Caution because the upside is real but conditional. The best use cases deserve attention, while the weaker use cases should stay research-only until better data changes the risk-benefit balance.
Key Evidence Sources
- Dorr et al. 1996 - Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study, Life Sciences. Pilot phase-I human study in which short low-dose subcutaneous MT-II produced measurable skin pigmentation, with mild nausea and spontaneous erections as side effects.
- Wessells et al. 1998 - Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo-controlled crossover study, The Journal of Urology. Crossover trial in which MT-II produced far longer penile tip rigidity than placebo (about 38 minutes versus 3 minutes) in men with psychogenic erectile dysfunction.
- Wessells et al. 2000 - Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction, Urology. Trial in men with organic erectile dysfunction where MT-II produced reported erections after 12 of 19 injections versus 1 of 21 placebo doses.
- Wessells et al. 2000 - Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II, International Journal of Impotence Research. Human synthesis describing MT-II as a potent initiator of penile erection and sexual motivation through melanocortin receptor activity.
- Fan et al. 1997 - Role of melanocortinergic neurons in feeding and the agouti obesity syndrome, Nature. Showed that melanocortin neurons tonically suppress feeding, which explains how MC4R-active compounds like MT-II reduce appetite.
- Hjuler et al. 2014 - Melanoma associated with the use of melanotan-II, Dermatology. Case report linking development of melanoma to the use of melanotan-II.
- Nelson et al. 2012 - Melanotan II injection resulting in systemic toxicity and rhabdomyolysis, Clinical Toxicology. Case of systemic toxicity and rhabdomyolysis following Melanotan II injection.
- Kaski et al. 2013 - Melanotan and the posterior reversible encephalopathy syndrome, Annals of Internal Medicine. Case report of posterior reversible encephalopathy syndrome in a woman after subcutaneous melanotan use.
- Peters et al. 2020 - Melanotan II: a possible cause of renal infarction: review of the literature and case report, CEN Case Reports. Case and literature review linking MT-II to renal infarction through possible thrombotic and direct toxic effects on the kidney.
- Mallory et al. 2021 - Melanotan Tanning Injection: A Rare Cause of Priapism, Sexual Medicine. Case of acute ischemic priapism after a Melanotan tanning injection, treated with penoscrotal decompression.
What does the evidence say about Melanotan II?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Limited
Citations: Dorr 1996, Wessells 1998, Wessells 2000, Fan 1997, Nelson 2012, Kaski 2013, Peters 2020, Hjuler 2014
Pre-RCT-Era Pharmacology and Use
Citations: Dorr 1996
Traditional Medicine Systems
Citations: Dorr 1996
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Vitamin D Baseline (pre-protocol)
- Liver Enzymes During | Expected Stable
- Dermatology Skin Exam Baseline (pre-protocol) Post | Expected Watch
Pulse Dimensions to Watch
- Body During | Expected Up | Primary
- Drive During | Expected Watch | Secondary
- Calm During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Sun Tolerance Scale 1-5 | During | Expected Up
- Nausea Or Flushing Scale 1-5 | During | Expected Watch
- New Or Changing Moles Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- New or rapidly changing mole, oral pigmentation, or bleeding lesion
- Severe headache, confusion, vision change, chest pain, or neurologic symptoms
- Priapism, severe abdominal pain, dark urine, or muscle pain after dosing
Other interventions for Skin & Beauty
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.250 − 2.652 = -0.402
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (-0.402 / 5.36) × 5 = 4.6 / 10
Further learning
Sun Protection Without Sunscreen: Ultimate 2026 Guide for Layered UV Defense
Sunscreen isn't enough when dealing with heavy sunlight exposure. In this guide, we discuss the different mechanisms for you to reap the benefits of…
“Internal Sunscreen”, Skin Peptides, & Renegade Beauty
This deep dive will teach you the most current natural and effective strategies to bioharmonize your beauty, aesthetics, and personal care.
